Possible changes in intraocular pressure measurements after corneal collagen cross-linking with riboflavin and ultraviolet A in eyes with keratoconus
Journal of the Egyptian Ophthalmological Society · 2013
DOI: 10.4103/2090-0686.127378 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Egyptian Ophthalmological Society, 2013. Verfasst von ImanM Eissa und 2 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
PurposeThe aim of the study was to determine the possible effect of corneal collagen cross-linking (CXL) with riboflavin and ultraviolet A on intraocular pressure (IOP) measurements using Goldmann applanation tonometry (GAT) in eyes with keratoconus.DesignThe study was designed as a prospective case series and conducted in Al Haram Eye Center and RCC Hospital, Giza, Egypt.Materials and methodsThis noncomparative study measured IOP using GAT before CXL and at 3, 6, and 12 months after CXL.ResultsThe study evaluated 49 eyes (40 patients). There was a statistically significant increase in the measured IOP at 3, 6, and 12 months after CXL (P
Zitieren
APA
Eissa, I., El-Husseiny, M., & Ismail, A. (2013). Possible changes in intraocular pressure measurements after corneal collagen cross-linking with riboflavin and ultraviolet A in eyes with keratoconus. Journal of the Egyptian Ophthalmological Society. https://doi.org/10.4103/2090-0686.127378
Vancouver
Eissa I, El-Husseiny M, Ismail A. Possible changes in intraocular pressure measurements after corneal collagen cross-linking with riboflavin and ultraviolet A in eyes with keratoconus. Journal of the Egyptian Ophthalmological Society. 2013. doi:10.4103/2090-0686.127378
BibTeX
@article{Eissa2013,
author = {Eissa, ImanM and El-Husseiny, MostafaA and Ismail, Ahmad},
title = {Possible changes in intraocular pressure measurements after corneal collagen cross-linking with riboflavin and ultraviolet A in eyes with keratoconus},
journal = {Journal of the Egyptian Ophthalmological Society},
year = {2013},
doi = {10.4103/2090-0686.127378}
}
EUVIMED